Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2012; 2(6):577-588. doi:10.7150/thno.4443 This issue Cite

Research Paper

Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin αvβ3-Targeted Radiotracer 99mTc-3P-RGD2

Yang Zhou1, Guoqiang Shao1,2, Shuang Liu1✉

1. School of Health Sciences, Purdue University, IN 47907, USA.
2. Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.

✉ Corresponding author: Dr. Shuang Liu, School of Health Sciences, Purdue University, 550 Stadium Mall Drive, West Lafayette, Indiana 47907. Phone: 765-494-0236; Fax 765-496-1377; Email: liu100purdue.edu

Citation:
Zhou Y, Shao G, Liu S. Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin αvβ3-Targeted Radiotracer 99mTc-3P-RGD2. Theranostics 2012; 2(6):577-588. doi:10.7150/thno.4443. https://www.thno.org/v02p0577.htm
Other styles

File import instruction

Abstract

Purpose: The purpose of this study was to evaluate the capability of u-SPECT-II/CT to monitor the progression of breast cancer lung metastasis using 99mTc-3P-RGD2 as a radiotracer.

Methods: The breast cancer lung metastasis model was established by tail-vein injection of 2 x 105 - 1.5 x 106 MDA-MB-231 cells into each athymic nude mouse. SPECT/CT studies were performed at a specified time after inoculation of MDA-MB-231 cells. Histological staining was used to further confirm the presence of lung metastases.

Results: We found that both inoculation time and tumor cell load had significant influence on the extent of lung metastasis. For example, if animals were injected with 2 x 105 MDA-MB-231 cells, there were no detectable metastatic breast tumors in the lungs after 8 weeks. If animals were injected with 1 x 106 MDA-MB-231 cells, there were many tumors in both lungs at week 8. When 1.5 x 106 MDA-MB-231 cells were injected, the animal became very weak by week 7. We also found a rare example of breast cancer metastasis in the muscle and mediastinal lymph nodes. The tumor necrotic regions were clearly delineated by u-SPECT-II/CT.

Conclusion: This study clearly demonstrated that 99mTc-3P-RGD2 is an excellent radiotracer for noninvasive imaging of metastatic breast tumors in the lungs, mediastinal lymph nodes and muscles. 99mTc-3P-RGD2 SPECT/CT is an outstanding platform for monitoring the progression of breast cancer lung metastases, semi-quantification of breast tumor load in the lungs and delineation of tumor necrosis in small animals.

Keywords: Breast Cancer Lung Metastasis, 99mTc-3P-RGD2, u-SPECT-II/CT.

Citation styles

APA
Zhou, Y., Shao, G., Liu, S. (2012). Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin αvβ3-Targeted Radiotracer 99mTc-3P-RGD2. Theranostics, 2(6), 577-588. https://doi.org/10.7150/thno.4443.

ACS
Zhou, Y.; Shao, G.; Liu, S. Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin αvβ3-Targeted Radiotracer 99mTc-3P-RGD2. Theranostics 2012, 2 (6), 577-588. DOI: 10.7150/thno.4443.

NLM
Zhou Y, Shao G, Liu S. Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin αvβ3-Targeted Radiotracer 99mTc-3P-RGD2. Theranostics 2012; 2(6):577-588. doi:10.7150/thno.4443. https://www.thno.org/v02p0577.htm

CSE
Zhou Y, Shao G, Liu S. 2012. Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin αvβ3-Targeted Radiotracer 99mTc-3P-RGD2. Theranostics. 2(6):577-588.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use